Literature DB >> 17471565

Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review.

M J Bermejo-Pérez1, S Márquez-Calderón, A Llanos-Méndez.   

Abstract

A systematic review of the literature was conducted to assess the outcomes of preventive interventions (prophylactic surgery, intensive cancer screening, and chemoprevention) in women who carry mutations in BRCA1/2 genes, in terms of reducing breast and gynaecological cancer incidence and/or mortality. A search for relevant articles published between 1996 and 2005 (inclusive) was run on Medline, Embase and other databases. From the 749 journal articles retrieved from this search strategy, 18 studies were eligible for this review (2 systematic reviews, 10 cohort studies and 6 case-control studies). The critical appraisal of the studies was performed by two independent reviewers with a list of ad hoc selected criteria. The synthesis of results was qualitative. Mastectomy and prophylactic gynaecological surgery (oophorectomy or salpingo-oophorectomy) reduced breast and gynaecological cancer incidence in carriers of BRCA mutations, by comparison to surveillance. However, all the studies presented flaws in internal and external validity, none of these preventive interventions is risk-free, and protection against breast and gynaecological cancer, as well as other cancers linked to BRCA mutations, is incomplete. No studies comparing surveillance programmes of varying intensity were found. Exposure to drugs (tamoxifen, and oral contraceptives) in women carrying BRCA mutations was assessed through a limited number of papers. All of these were case-control studies with prevalent cases and presented major methodological flaws. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17471565     DOI: 10.1002/ijc.22817

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

1.  Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.

Authors:  Mary S Beattie; Beth Crawford; Feng Lin; Eric Vittinghoff; John Ziegler
Journal:  Genet Test Mol Biomarkers       Date:  2009-02

2.  Evaluation after five years of the cancer genetic counselling programme of Valencian Community (Eastern Spain).

Authors:  Dolores Cuevas-Cuerda; Dolores Salas-Trejo
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

3.  Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes.

Authors:  Lídia Feliubadaló; Adriana Lopez-Doriga; Ester Castellsagué; Jesús del Valle; Mireia Menéndez; Eva Tornero; Eva Montes; Raquel Cuesta; Carolina Gómez; Olga Campos; Marta Pineda; Sara González; Victor Moreno; Joan Brunet; Ignacio Blanco; Eduard Serra; Gabriel Capellá; Conxi Lázaro
Journal:  Eur J Hum Genet       Date:  2012-12-19       Impact factor: 4.246

4.  Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.

Authors:  R Kreienberg; U-S Albert; M Follmann; I B Kopp; T Kühn; A Wöckel
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-06       Impact factor: 2.915

5.  The process of deciding about prophylactic surgery for breast and ovarian cancer: Patient questions, uncertainties, and communication.

Authors:  Robert Klitzman; Wendy Chung
Journal:  Am J Med Genet A       Date:  2010-01       Impact factor: 2.802

6.  Self administered screening for hereditary cancers in conjunction with mammography and ultrasound.

Authors:  Charles H McDonnell; David J Seidenwurm; Diana E McDonnell; Kristie A Bobolis
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

7.  Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations.

Authors:  Daniel H Kim; Beth Crawford; John Ziegler; Mary S Beattie
Journal:  Fam Cancer       Date:  2008-10-15       Impact factor: 2.375

8.  Female BRCA mutation carriers with a preference for prophylactic mastectomy are more likely to participate an educational-support group and to proceed with the preferred intervention within 2 years.

Authors:  Karin M Landsbergen; Judith B Prins; Yvonne J L Kamm; Han G Brunner; Nicoline Hoogerbrugge
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

Review 9.  The contribution of BRCA1 and BRCA2 to ovarian cancer.

Authors:  Susan J Ramus; Simon A Gayther
Journal:  Mol Oncol       Date:  2009-02-10       Impact factor: 6.603

Review 10.  Breast cancer in young women and its impact on reproductive function.

Authors:  M Hickey; M Peate; C M Saunders; M Friedlander
Journal:  Hum Reprod Update       Date:  2009-01-27       Impact factor: 15.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.